Literature DB >> 33221805

Hematological Manifestations among Patients with Rheumatic Diseases.

Alina Klein1, Yair Molad2,3.   

Abstract

BACKGROUND: Rheumatic diseases have many hematological manifestations. Blood dyscrasias and other hematological abnormalities are sometimes the first sign of rheumatic disease. In addition, novel antirheumatic biological agents may cause cytopenias.
SUMMARY: The aim of this review was to discuss cytopenias caused by systemic lupus erythematosus and antirheumatic drugs, Felty's syndrome in rheumatoid arthritis, and autoimmune hemolytic anemia, thrombosis, and thrombotic microangiopathies related to rheumatological conditions such as catastrophic antiphospholipid syndrome and scleroderma renal crisis. Key Message: The differential diagnosis of various hematological disorders should include rheumatic autoimmune diseases among other causes of blood cell and hemostasis abnormalities. It is crucial that hematologists be aware of these presentations so that they are diagnosed and treated in a timely manner.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Anemia; Antiphospholipid syndrome; Arthritis; Leukopenia; Rheumatic diseases; Systemic lupus erythematosus; Thrombocytopenia; Thrombosis; Thrombotic microangiopathy; Vasculitis

Year:  2020        PMID: 33221805     DOI: 10.1159/000511759

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  4 in total

Review 1.  Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus.

Authors:  Wenjun Yuan; Fengjun Guan
Journal:  Autoimmune Dis       Date:  2022-06-27

2.  Microangiopathy in Inflammatory Diseases-Strategies in Surgery of the Lower Extremity.

Authors:  Christoph Biehl; Lotta Biehl; Ingo Helmut Tarner; Ulf Müller-Ladner; Christian Heiss; Martin Heinrich
Journal:  Life (Basel)       Date:  2022-01-28

Review 3.  Autoimmune hemolytic anemia as an initial presentation in children with systemic lupus erythematosus: two case reports.

Authors:  Yan Lu; Xian-Mei Huang
Journal:  J Int Med Res       Date:  2022-08       Impact factor: 1.573

Review 4.  A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.

Authors:  Thomas Bieber; Eugen Feist; Alan D Irvine; Masayoshi Harigai; Ewa Haladyj; Susan Ball; Walter Deberdt; Maher Issa; Susanne Grond; Peter C Taylor
Journal:  Adv Ther       Date:  2022-09-05       Impact factor: 4.070

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.